26 September 2024 - Vertex Pharmaceuticals today announced that Health Canada has accepted for review its new drug submission for vanzacaftor/tezacaftor/deutivacaftor, a once daily triple combination therapy for people living with cystic fibrosis ages 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator gene.

The new drug submission will be part of an aligned review with Canadian Health Technology Assessment organizations, Canada's Drug Agency and the Institut national d'excellence en santé et en services sociaux (INESSS) in Quebec.

Read Vertex Pharmaceuticals press release